Hollie Franklin, Author at Drugs in Context

Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease

Caterina Vacchi PhD, Andreina Manfredi MD, Giulia Cassone PhD, Gian Luca Erre MD, Carlo Salvarani MD, Marco Sebastiani MD

Article Type

Review

Published

15 Jan 2021

This article reviews the available efficacy and safety data on the use of rituximab in the treatment of rheumatic disease-related interstitial lung disease.

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications

Gian Luca Erre MD, PhD, Marco Sebastiani PhD, Andreina Manfredi MD, Elisabetta Gerratana MD, Fabiola Atzeni MD, Giuseppe Passiu MD, Arduino A Mangoni MD

Article Type

Review

Published

15 Jan 2021

This review discusses the experimental evidence and clinical trials investigating the efficacy and safety of antifibrotic drugs in patients with CTD-ILDs and the potential mechanisms of action involved.

Key policy and programmatic factors to improve influenza vaccination rates based on the experience from four high-performing countries

George Kassianos MD, Ashis Banerjee MD, Florence Baron-Papillon MD, Alan W Hampson MD, Janet E McElhaney MD, Allison McGeer MD, Thierry Rigoine de Fougerolles MSc, Mitch Rothholz MD, Holly Seale MD, Litjen J Tan MD, Angus Thomson PhD, Olivier Vitoux MSc

Article Type

Review

Published

05 Jan 2021

The aim of this analysis was to identify factors that have been instrumental in achieving a high influenza vaccine coverage rate (VCR) in the scope of four benchmark countries in order to provide an organised list of factors that could be used by countries with lower VCRs to help improve and strengthen their own VCRs.

Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis

George J Wan PhD, Ishveen Chopra PhD, John Niewoehner PharmD, Samuel F Hunter MD, PhD

Article Type

Original Research

Published

16 Dec 2020

The objective of this study was to estimate the cost per response of repository corticotropin injection compared with plasmapheresis or intravenous immunoglobulin from the United States commercial payer perspective.

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Rodolfo Sacco MD, PhD, Vincenzo Messina MD, Umberto Vespasiani Gentilucci MD, Luigi Elio Adinolfi MD, Antonio Ascione MD, Giorgio Barbarini MD, Angelo Barlattani MD, Giuseppe Cariti MD, Raffaele Cozzolongo MD, Basilio Fimiani MD, Ruggiero Francavilla MD, Caterina Furlan MD, Giovanni Garrucciu MD, Vincenzo Iovinella MD, Luca Rinaldi MD, Massimo Marignani MD, Paola Begini MD, Valeria Pace Palitti MD, Adriano M Pellicelli MD, Gaetano Scifo MD, Antonio Facciorusso MD, Luca Giacomelli PhD, Aashni Shah BSc, Gaetano Bertino MD, Serena Perazzo MD, Giampaolo Bresci MD, Antonio Izzi MD

Article Type

Original Research

Published

15 Dec 2020

The aim of this retrospective, multicenter, field-practice study was to investigate the therapeutic efficacy and safety of the oral combination of daclatasvir and sofosbuvir, with or without ribavirin, in a large unselected cohort of patients with chronic hepatitis C virus infection.